Stocrin Re-examination Study (0831-028)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: HIV Infection

Study type: Observational

Funder types: Industry

Identifiers

NCT01065792

2010_008 (Other Identifier)

0831-028

Details and patient eligibility

About

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of STOCRIN through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Enrollment: 728 patients

Sex: All

Ages: 3+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-1 Infected Patient
• Patient Who Is Treated With Stocrin 600 Mg Tablet Within Local Label During The Enrollment Period (A Patient Who Changes The Therapy From Stocrin 200 Mg Capsule To Stocrin 600 Mg Tablet Can Be Eligible.)

Exclusion criteria

• Patient Who Has A Contraindication To Stocrin According To The Local Label

Trial design

728 participants in 1 patient group

1

Description:

Patients with HIV-1 infection taking Stocrin